Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1)
Objective To assess the effects of intravenous administration of magnesium on complex regional pain syndrome type 1 (CRPS‐1), a randomized double‐blind placebo‐controlled trial was performed. Methods Fifty‐six patients with CRPS‐1 (International Association for the Study of Pain Orlando criteria) re...
Gespeichert in:
| Veröffentlicht in: | Pain medicine (Malden, Mass.) Mass.), 2013-09, Vol.14 (9), p.1388-1399 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1399 |
|---|---|
| container_issue | 9 |
| container_start_page | 1388 |
| container_title | Pain medicine (Malden, Mass.) |
| container_volume | 14 |
| creator | Fischer, Sigrid G. L. Collins, Susan Boogaard, Sabine Loer, Stephan A. Zuurmond, Wouter W. A. Perez, Roberto S. G. M. |
| description | Objective
To assess the effects of intravenous administration of magnesium on complex regional pain syndrome type 1 (CRPS‐1), a randomized double‐blind placebo‐controlled trial was performed.
Methods
Fifty‐six patients with CRPS‐1 (International Association for the Study of Pain Orlando criteria) received MgSO4 70 mg/kg or placebo (NaCl 0.9%) in 4 hours over 5 consecutive days. Pain (BOX‐11 and McGill), the level of impairment (Impairment level Sum Score [ISS]), functional limitations (Radboud Skills Questionnaire, Walking Skills Questionnaire/questionnaire rising and sitting down), participation (Impact on Participation and Autonomy [IPA]), and quality of life (Short Form‐36, EuroQol, IPA) were evaluated at baseline and at 1, 3, 6, and 12 weeks.
Results
No significant differences were found between MgSO4 and placebo on the BOX‐11 and ISS at different time points during the trial on intention‐to‐treat and per‐protocol analysis. A significant improvement on the BOX‐11 was found after the first week of the trial in both groups (mean 0.7; standard deviation 1.1). For the MgSO4 group, a clinically relevant and statistically significant improvement on the ISS at 1 week (median 5, interquartile range [IQR] –1 to 8) and a significant improvement on the McGill up to 6 weeks (median 2 words, IQR 0–4.5) were found compared with baseline, which were not found in the placebo group. Significant improvement in perceived job participation was found for the MgSO4 group at 12 weeks (median improvement 1.44–1.17; P = 0.01). ISS improved significantly more in patients with a low Hospital Anxiety and Depression Scale (HADS) score (≤10) in the MgSO4 group (mean 4.4 vs mean −3.1; P = 0.02).
Conclusion
Administration of the physiological competitive N‐methyl‐D‐aspartate receptor antagonist magnesium in chronic CRPS provides insufficient benefit over placebo. Future research should focus on patients with acute CRPS and early signs and symptoms of central sensitization. |
| doi_str_mv | 10.1111/pme.12211 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1432620266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1432620266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4131-2a35496912dde526bf727135f5ec79e6741561392db1c88a95e5b71286763dad3</originalsourceid><addsrcrecordid>eNp10EtOwzAQBmALgXgvuACyxAYWLRnbceIlinhJrajaso7cZFKCkjjYDdAdR-CMnARDCwskZuNZfPrl-Qk5gqAPfs7bGvvAGMAG2YWQyZ6QPNpc74xH4Q7Zc-4xCECKmG-THcbjWCkR7JLxbbOw-hkb0zk61PMGXdnVtDCWJg_WNGVGE1O3Fb7SMc5L0-iKjnTZ0Mmyya2pkU6XLVKgp8l4NPl4e4ezA7JV6Mrh4frdJ_dXl9Pkpje4u75NLga9TACHHtM8FEoqYHmO_qOzImIR8LAIMYsUykhAKIErls8gi2OtQgxnEbBYRpLnOuf75HSV21rz1KFbpHXpMqwq3aC_JgXBmWQBk9LTkz_00XTW3_KtQHElYuHV2Upl1jhnsUhbW9baLlMI0q-iU190-l20t8frxG5WY_4rf5r14HwFXsoKl_8npaPh5SryE_PGhJk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1431939484</pqid></control><display><type>article</type><title>Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Fischer, Sigrid G. L. ; Collins, Susan ; Boogaard, Sabine ; Loer, Stephan A. ; Zuurmond, Wouter W. A. ; Perez, Roberto S. G. M.</creator><creatorcontrib>Fischer, Sigrid G. L. ; Collins, Susan ; Boogaard, Sabine ; Loer, Stephan A. ; Zuurmond, Wouter W. A. ; Perez, Roberto S. G. M.</creatorcontrib><description>Objective
To assess the effects of intravenous administration of magnesium on complex regional pain syndrome type 1 (CRPS‐1), a randomized double‐blind placebo‐controlled trial was performed.
Methods
Fifty‐six patients with CRPS‐1 (International Association for the Study of Pain Orlando criteria) received MgSO4 70 mg/kg or placebo (NaCl 0.9%) in 4 hours over 5 consecutive days. Pain (BOX‐11 and McGill), the level of impairment (Impairment level Sum Score [ISS]), functional limitations (Radboud Skills Questionnaire, Walking Skills Questionnaire/questionnaire rising and sitting down), participation (Impact on Participation and Autonomy [IPA]), and quality of life (Short Form‐36, EuroQol, IPA) were evaluated at baseline and at 1, 3, 6, and 12 weeks.
Results
No significant differences were found between MgSO4 and placebo on the BOX‐11 and ISS at different time points during the trial on intention‐to‐treat and per‐protocol analysis. A significant improvement on the BOX‐11 was found after the first week of the trial in both groups (mean 0.7; standard deviation 1.1). For the MgSO4 group, a clinically relevant and statistically significant improvement on the ISS at 1 week (median 5, interquartile range [IQR] –1 to 8) and a significant improvement on the McGill up to 6 weeks (median 2 words, IQR 0–4.5) were found compared with baseline, which were not found in the placebo group. Significant improvement in perceived job participation was found for the MgSO4 group at 12 weeks (median improvement 1.44–1.17; P = 0.01). ISS improved significantly more in patients with a low Hospital Anxiety and Depression Scale (HADS) score (≤10) in the MgSO4 group (mean 4.4 vs mean −3.1; P = 0.02).
Conclusion
Administration of the physiological competitive N‐methyl‐D‐aspartate receptor antagonist magnesium in chronic CRPS provides insufficient benefit over placebo. Future research should focus on patients with acute CRPS and early signs and symptoms of central sensitization.</description><identifier>ISSN: 1526-2375</identifier><identifier>EISSN: 1526-4637</identifier><identifier>DOI: 10.1111/pme.12211</identifier><identifier>PMID: 23889940</identifier><identifier>CODEN: PMAEAP</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Analgesics - administration & dosage ; Central Sensitization ; CRPS‐1 ; Double-Blind Method ; Female ; Humans ; Infusions, Intravenous ; Magnesium ; Magnesium Sulfate - administration & dosage ; Male ; Middle Aged ; NMDA Receptor ; Pain Threshold - drug effects ; Quality of Life ; Questionnaires ; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors ; Reflex Sympathetic Dystrophy - drug therapy</subject><ispartof>Pain medicine (Malden, Mass.), 2013-09, Vol.14 (9), p.1388-1399</ispartof><rights>Wiley Periodicals, Inc</rights><rights>Wiley Periodicals, Inc.</rights><rights>2013 American Academy of Pain Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4131-2a35496912dde526bf727135f5ec79e6741561392db1c88a95e5b71286763dad3</citedby><cites>FETCH-LOGICAL-c4131-2a35496912dde526bf727135f5ec79e6741561392db1c88a95e5b71286763dad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpme.12211$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpme.12211$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23889940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fischer, Sigrid G. L.</creatorcontrib><creatorcontrib>Collins, Susan</creatorcontrib><creatorcontrib>Boogaard, Sabine</creatorcontrib><creatorcontrib>Loer, Stephan A.</creatorcontrib><creatorcontrib>Zuurmond, Wouter W. A.</creatorcontrib><creatorcontrib>Perez, Roberto S. G. M.</creatorcontrib><title>Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1)</title><title>Pain medicine (Malden, Mass.)</title><addtitle>Pain Med</addtitle><description>Objective
To assess the effects of intravenous administration of magnesium on complex regional pain syndrome type 1 (CRPS‐1), a randomized double‐blind placebo‐controlled trial was performed.
Methods
Fifty‐six patients with CRPS‐1 (International Association for the Study of Pain Orlando criteria) received MgSO4 70 mg/kg or placebo (NaCl 0.9%) in 4 hours over 5 consecutive days. Pain (BOX‐11 and McGill), the level of impairment (Impairment level Sum Score [ISS]), functional limitations (Radboud Skills Questionnaire, Walking Skills Questionnaire/questionnaire rising and sitting down), participation (Impact on Participation and Autonomy [IPA]), and quality of life (Short Form‐36, EuroQol, IPA) were evaluated at baseline and at 1, 3, 6, and 12 weeks.
Results
No significant differences were found between MgSO4 and placebo on the BOX‐11 and ISS at different time points during the trial on intention‐to‐treat and per‐protocol analysis. A significant improvement on the BOX‐11 was found after the first week of the trial in both groups (mean 0.7; standard deviation 1.1). For the MgSO4 group, a clinically relevant and statistically significant improvement on the ISS at 1 week (median 5, interquartile range [IQR] –1 to 8) and a significant improvement on the McGill up to 6 weeks (median 2 words, IQR 0–4.5) were found compared with baseline, which were not found in the placebo group. Significant improvement in perceived job participation was found for the MgSO4 group at 12 weeks (median improvement 1.44–1.17; P = 0.01). ISS improved significantly more in patients with a low Hospital Anxiety and Depression Scale (HADS) score (≤10) in the MgSO4 group (mean 4.4 vs mean −3.1; P = 0.02).
Conclusion
Administration of the physiological competitive N‐methyl‐D‐aspartate receptor antagonist magnesium in chronic CRPS provides insufficient benefit over placebo. Future research should focus on patients with acute CRPS and early signs and symptoms of central sensitization.</description><subject>Adult</subject><subject>Analgesics - administration & dosage</subject><subject>Central Sensitization</subject><subject>CRPS‐1</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Magnesium</subject><subject>Magnesium Sulfate - administration & dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NMDA Receptor</subject><subject>Pain Threshold - drug effects</subject><subject>Quality of Life</subject><subject>Questionnaires</subject><subject>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</subject><subject>Reflex Sympathetic Dystrophy - drug therapy</subject><issn>1526-2375</issn><issn>1526-4637</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10EtOwzAQBmALgXgvuACyxAYWLRnbceIlinhJrajaso7cZFKCkjjYDdAdR-CMnARDCwskZuNZfPrl-Qk5gqAPfs7bGvvAGMAG2YWQyZ6QPNpc74xH4Q7Zc-4xCECKmG-THcbjWCkR7JLxbbOw-hkb0zk61PMGXdnVtDCWJg_WNGVGE1O3Fb7SMc5L0-iKjnTZ0Mmyya2pkU6XLVKgp8l4NPl4e4ezA7JV6Mrh4frdJ_dXl9Pkpje4u75NLga9TACHHtM8FEoqYHmO_qOzImIR8LAIMYsUykhAKIErls8gi2OtQgxnEbBYRpLnOuf75HSV21rz1KFbpHXpMqwq3aC_JgXBmWQBk9LTkz_00XTW3_KtQHElYuHV2Upl1jhnsUhbW9baLlMI0q-iU190-l20t8frxG5WY_4rf5r14HwFXsoKl_8npaPh5SryE_PGhJk</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Fischer, Sigrid G. L.</creator><creator>Collins, Susan</creator><creator>Boogaard, Sabine</creator><creator>Loer, Stephan A.</creator><creator>Zuurmond, Wouter W. A.</creator><creator>Perez, Roberto S. G. M.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1)</title><author>Fischer, Sigrid G. L. ; Collins, Susan ; Boogaard, Sabine ; Loer, Stephan A. ; Zuurmond, Wouter W. A. ; Perez, Roberto S. G. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4131-2a35496912dde526bf727135f5ec79e6741561392db1c88a95e5b71286763dad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Analgesics - administration & dosage</topic><topic>Central Sensitization</topic><topic>CRPS‐1</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Magnesium</topic><topic>Magnesium Sulfate - administration & dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NMDA Receptor</topic><topic>Pain Threshold - drug effects</topic><topic>Quality of Life</topic><topic>Questionnaires</topic><topic>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</topic><topic>Reflex Sympathetic Dystrophy - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fischer, Sigrid G. L.</creatorcontrib><creatorcontrib>Collins, Susan</creatorcontrib><creatorcontrib>Boogaard, Sabine</creatorcontrib><creatorcontrib>Loer, Stephan A.</creatorcontrib><creatorcontrib>Zuurmond, Wouter W. A.</creatorcontrib><creatorcontrib>Perez, Roberto S. G. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pain medicine (Malden, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fischer, Sigrid G. L.</au><au>Collins, Susan</au><au>Boogaard, Sabine</au><au>Loer, Stephan A.</au><au>Zuurmond, Wouter W. A.</au><au>Perez, Roberto S. G. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1)</atitle><jtitle>Pain medicine (Malden, Mass.)</jtitle><addtitle>Pain Med</addtitle><date>2013-09</date><risdate>2013</risdate><volume>14</volume><issue>9</issue><spage>1388</spage><epage>1399</epage><pages>1388-1399</pages><issn>1526-2375</issn><eissn>1526-4637</eissn><coden>PMAEAP</coden><abstract>Objective
To assess the effects of intravenous administration of magnesium on complex regional pain syndrome type 1 (CRPS‐1), a randomized double‐blind placebo‐controlled trial was performed.
Methods
Fifty‐six patients with CRPS‐1 (International Association for the Study of Pain Orlando criteria) received MgSO4 70 mg/kg or placebo (NaCl 0.9%) in 4 hours over 5 consecutive days. Pain (BOX‐11 and McGill), the level of impairment (Impairment level Sum Score [ISS]), functional limitations (Radboud Skills Questionnaire, Walking Skills Questionnaire/questionnaire rising and sitting down), participation (Impact on Participation and Autonomy [IPA]), and quality of life (Short Form‐36, EuroQol, IPA) were evaluated at baseline and at 1, 3, 6, and 12 weeks.
Results
No significant differences were found between MgSO4 and placebo on the BOX‐11 and ISS at different time points during the trial on intention‐to‐treat and per‐protocol analysis. A significant improvement on the BOX‐11 was found after the first week of the trial in both groups (mean 0.7; standard deviation 1.1). For the MgSO4 group, a clinically relevant and statistically significant improvement on the ISS at 1 week (median 5, interquartile range [IQR] –1 to 8) and a significant improvement on the McGill up to 6 weeks (median 2 words, IQR 0–4.5) were found compared with baseline, which were not found in the placebo group. Significant improvement in perceived job participation was found for the MgSO4 group at 12 weeks (median improvement 1.44–1.17; P = 0.01). ISS improved significantly more in patients with a low Hospital Anxiety and Depression Scale (HADS) score (≤10) in the MgSO4 group (mean 4.4 vs mean −3.1; P = 0.02).
Conclusion
Administration of the physiological competitive N‐methyl‐D‐aspartate receptor antagonist magnesium in chronic CRPS provides insufficient benefit over placebo. Future research should focus on patients with acute CRPS and early signs and symptoms of central sensitization.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>23889940</pmid><doi>10.1111/pme.12211</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-2375 |
| ispartof | Pain medicine (Malden, Mass.), 2013-09, Vol.14 (9), p.1388-1399 |
| issn | 1526-2375 1526-4637 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1432620266 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Analgesics - administration & dosage Central Sensitization CRPS‐1 Double-Blind Method Female Humans Infusions, Intravenous Magnesium Magnesium Sulfate - administration & dosage Male Middle Aged NMDA Receptor Pain Threshold - drug effects Quality of Life Questionnaires Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Reflex Sympathetic Dystrophy - drug therapy |
| title | Intravenous Magnesium for Chronic Complex Regional Pain Syndrome Type 1 (CRPS‐1) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T10%3A44%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20Magnesium%20for%20Chronic%20Complex%20Regional%20Pain%20Syndrome%20Type%201%20(CRPS%E2%80%901)&rft.jtitle=Pain%20medicine%20(Malden,%20Mass.)&rft.au=Fischer,%20Sigrid%20G.%20L.&rft.date=2013-09&rft.volume=14&rft.issue=9&rft.spage=1388&rft.epage=1399&rft.pages=1388-1399&rft.issn=1526-2375&rft.eissn=1526-4637&rft.coden=PMAEAP&rft_id=info:doi/10.1111/pme.12211&rft_dat=%3Cproquest_cross%3E1432620266%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1431939484&rft_id=info:pmid/23889940&rfr_iscdi=true |